Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
10 p, 426.6 KB A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies / Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Delord, J. P. (Institut Claudius Regaud (France)) ; Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ; Berge, Y. (Institut Claudius Regaud (France)) ; Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ; Cottura, E. (Institut Claudius Regaud (France)) ; Bedard, P. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Akimov, M. (Novartis Pharma AG (Switzerland)) ; Lu, H. (Novartis Pharmaceuticals Corp (USA)) ; Pain, S. (Novartis Pharmaceuticals Corp (USA)) ; Kaag, A. (Novartis Pharma AG (Switzerland)) ; Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Cortés Castán, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659  
2.
6 p, 263.8 KB A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer / Tan, E.H. (National Cancer Centre (Singapur). Department of Medical Oncology) ; Ramlau, R. (Regional Lung Disease Centre (Poznan). Department of Oncology) ; Pluzanska, A. (Regional Oncology Centre (Lodz, Polònia). Oncological Chemotherapy Clinic) ; Kuo, H. -P. (Chang Gung Memorial Hospital (Linkou, Taiwan). Department of Thoracic Medicine) ; Reck, M. (Hospital Grosshansdorf (Grosshansdorf, Alemanya). Department of Thoracic Oncology) ; Milanowski, J. (Akademia Medyczna w Lublinie (Lublin, Polònia). Department of Pneumology, Oncology and Allergology) ; Au, J. S. -K. (Queen Elizabeth Hospital (Hong Kong). Department of Clinical Oncology) ; Felip Font, Enriqueta (Hospitals Vall d'Hebron (Barcelona, Catalunya)) ; Yang, P. -C. (National Taiwan University Hospital (Taipei, Taiwan)) ; Damyanov, D. (Specialized Hospital for Active Treatment in Oncology (Sofia, Bulgaria)) ; Orlov, S. (Pavlov State Medical University. Research Institute of Pulmonology (Sant Petersburg, Rússia)) ; Akimov, M. (Hoffmann-La Roche (Basel, Suïssa)) ; Delmar, P. (Hoffmann-La Roche (Basel, Suïssa)) ; Essioux, L. (Hoffmann-La Roche (Basel, Suïssa)) ; Hillenbach, C. (Hoffmann-La Roche (Basel, Suïssa)) ; Klughammer, B. (Hoffmann-La Roche (Basel, Suïssa)) ; McLoughlin, P. (Hoffmann-La Roche (Basel, Suïssa)) ; Baselga Torres, Josep, 1959-, (Vall d'Hebron Hospitals)
Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. [...]
2010
Annals of oncology, Vol. 21, Issue 2 (2010) , p. 217-222  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.